#Trade Shows & Events
Webinar: CAR T cell metabolism and antitumor activity
Claim your seat now!
Engineered T cells expressing high-affinity chimeric antigen receptors (CARs) confer remarkable tumor specificity by recognizing patient-specific tumor antigens and triggering antitumor activities. CAR T-based cell therapy has been effective in treating B cell malignancies, but several challenges remain especially in targeting solid tumors. Research efforts are underway to overcome these challenges and improve the overall effectiveness and clinical efficacy of this promising cell-based immunotherapy.
In this webinar Jan Joseph Melenhorst (Cleveland Clinic), Sidi Chen (Yale University), and Anna Schurich (Kings College London) will present and discuss the latest research on developing and optimizing CAR T cells with improved metabolic and antitumor properties.
